MAP2 and Cognitive impairment: The cognitive impairments appear to be a result of progressive neuronal loss as determined by decreased immunoreactivity to neuronal markers such as NeuN and MAP2 and the loss of myelinated axons in CA1, probably coming from the CA3 and entorhinal cortex.